Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
세계 키메라 항원 수용체(CAR) T 세포 치료 시장 규모는 2024년 46억 달러에서 예측 기간 동안 40.2%의 CAGR(연평균 성장률)을 기록하며 2029년 말에는 251억 달러에 달할 것으로 예상됩니다.
Yescarta 시장 규모는 2024년 18억 달러에서 예측 기간 동안 36.7%의 CAGR로 2029년 말에는 87억 달러에 달할 것으로 예상되며, Carvykti 시장 규모는 2024년 7억 1,000만 달러에서 2029년 말에는 52.6%의 CAGR로 59억 달러에 달할 것으로 예상됩니다.
세계의 키메라 항원 수용체(CAR) T 세포 치료 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법·규제 환경, 신흥 기술 및 기술 개발 동향, 시장 규모 추정과 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
- 개요
- 시장과 기술 배경
- CAR-T 세포 치료 발전 경위
- FDA 제품 승인
- 기타 CAR-T 세포 치료
- CAR-T 세포 치료 임상 응용
- 양자 세포 이식(ACT) 기술
제3장 시장 역학
- 시장 역학
- 시장 성장 촉진요인
- 암 발생률 증가
- CAR-T 세포 치료 연구에 대한 투자와 자금 증가
- 강력한 연구개발 파이프라인
- 유전자 공학의 진보
- 시장 성장 억제요인
- 복잡한 법 및 규제 절차
- 경쟁 대체 제품
- 시장 기회
- 정밀의료의 중요성 상승
- CAR-T 세포 치료 응용 범위 확대
- 시장 과제
- 복잡한 제조와 공급망
- CAR-T 세포 치료 상환 과제
제4장 신기술과 임상시험
- 세계에서 행해지고 있는 임상시험
- 중국의 CAR-T 세포 임상시험 분포
제5장 시장 세분화 분석
- 중요한 포인트
- 세분화 내역
- 세계의 CAR-T 세포 치료 시장 : 제품별
- Yescarta
- Kymriah
- Tecartus
- Abecma
- Breyanzi
- Carvykti
- 세계의 CAR-T 세포 치료 시장 : 적응증별
- 지역적 내역
- 세계의 CAR-T 세포 치료 시장 : 지역별
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제6장 특허 리뷰와 새로운 전개
- 맞춤형 환자 치료에 관한 특허 소송 증가가 예상
- 기업 고유의 지적재산·특허 정보
- Amgen
- Avacta Life Sciences Ltd.
- Bluebird Bio
- Celgene Corp.
- Cellectis
- Celyad SA
- Editas Medicine Inc.
- Eureka Therapeutics Inc.
- iCell Gene Therapeutics
- Juno Therapeutics Inc.(A Celgene Co.)
- Noile-Immune Biotech
- Novartis AG
제7장 경쟁 정보
제8장 키메라 항원 수용체(CAR) T 세포 치료 시장의 지속가능성 : ESG 관점
- ESG : 소개
- 제약 업계에서 ESG의 역할
- ESG 퍼포먼스 분석
- 환경
- 사회
- 거버넌스
- ESG 리스크 평가
- 결론
제9장 부록
- 조사 방법
- 약어
- 참고문헌
- 기업 개요
- ABBVIE INC.
- ALLOGENE THERAPEUTICS
- AMGEN INC.
- ASTRAZENECA
- BLUEBIRD BIO INC.
- BRISTOL-MYERS SQUIBB CO.
- CELLECTIS S.A.
- EUREKA THERAPEUTICS INC.
- GILEAD SCIENCES INC.
- ICELL GENE THERAPEUTICS INC.
- JOHNSON & JOHNSON SERVICES INC.
- LES LABORATOIRES SERVIER
- NOVARTIS AG
- PFIZER INC.
- PROTHERAGEN INC.
ksm
The global market for CAR T-cell therapy is expected to grow from $4.6 billion in 2024 and projected to reach $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.
The global CAR T-cell therapy market for Yescarta is expected to grow from $1.8 billion in 2024 and projected to reach $8.7 billion by the end of 2029, at a CAGR of 36.7% from 2024 to 2029.
The global CAR T-cell therapy market for Carvykti is expected to grow from $710 million in 2024 and projected to reach $5.9 billion by the end of 2029, at a CAGR of 52.6% from 2024 to 2029.
Report Scope
This report incorporates an in-depth analysis of CAR T-cell therapy's current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies' business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.
Report Includes
- 14 data tables and 71 additional tables
- Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
- Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
- Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
- An analysis of patents, emerging trends and developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Market and Technology Background
- A Brief History of CAR T-Cell Therapy
- FDA Product Approvals
- Other CAR T-Cell Therapies
- Clinical Applications of CAR T-Cell Therapy
- Adoptive Cell Transfer (ACT) Technologies
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Increasing Incidence of Cancer
- Growing Investments and Funding in CAR T-Cell Therapy Research
- Robust R&D Pipeline
- Advances in Genetic Engineering
- Market Restraints
- Complex Legislative and Regulatory Procedures
- Alternative Products from Competitors
- Market Opportunities
- Growing Significance of Precision Medicine
- Expanding Applications for CAR T-Cell Therapy
- Market Challenges
- Complex Manufacturing and Supply Chain
- Reimbursement Challenges for CAR T-Cell Therapy
Chapter 4 Emerging Technologies and Clinical Trials
- Introduction
- Clinical Trials Being Conducted Globally
- Distribution of CAR T-Cell Clinical Trials in China
Chapter 5 Market Segmentation Analysis
- Key Takeaways
- Segmentation Breakdown
- Global Market for CAR T-Cell Therapy, by Product
- Yescarta
- Kymriah
- Tecartus
- Abecma
- Breyanzi
- Carvykti
- Global Market for CAR T-Cell Therapy, by Indication
- Geographic Breakdown
- Global Market for CAR T-Cell Therapy, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Patent Review and New Developments
- Introduction
- Anticipated Increase in Patent Litigation on Customized Patient Treatments
- Company-specific Intellectual Property and Patent Information
- Amgen
- Avacta Life Sciences Ltd.
- Bluebird Bio
- Celgene Corp.
- Cellectis
- Celyad SA
- Editas Medicine Inc.
- Eureka Therapeutics Inc.
- iCell Gene Therapeutics
- Juno Therapeutics Inc. (A Celgene Co.)
- Noile-Immune Biotech
- Novartis AG
Chapter 7 Competitive Intelligence
- Ranking of Leading Players
- Strategic Considerations
Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
- Introduction to ESG
- Role of ESG in the Pharma Industry
- ESG Performance Analysis
- Environmental
- Social
- Governance
- ESG Risk Ratings
- Conclusion
Chapter 9 Appendix
- Methodology
- Abbreviations
- References
- Company Profiles
- ABBVIE INC.
- ALLOGENE THERAPEUTICS
- AMGEN INC.
- ASTRAZENECA
- BLUEBIRD BIO INC.
- BRISTOL-MYERS SQUIBB CO.
- CELLECTIS S.A.
- EUREKA THERAPEUTICS INC.
- GILEAD SCIENCES INC.
- ICELL GENE THERAPEUTICS INC.
- JOHNSON & JOHNSON SERVICES INC.
- LES LABORATOIRES SERVIER
- NOVARTIS AG
- PFIZER INC.
- PROTHERAGEN INC.
